Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Hanryu Holdings, Inc. - Common Stock (NQ: HRYU )

0.4336 -0.0013 (-0.30%)
Streaming Delayed Price Updated: 10:00 AM EDT, May 23, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Hanryu Holdings, Inc. - Common Stock

< Previous 1 2 3 4 Next >
Hanryu Holdings' Application, FANTOO, Exclusively Markets and Hosts User Voting for Historical Asia Model Festival
Via ACCESSWIRE
Why PhenomeX Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Novo Integrated Sciences, Inc. (NASDAQ: NVOS) jumped 85.4% to $0.1267 after the company and Farm 7 Group announced a joint venture for Kenya Agricultural Cooperative Project. 
Via Benzinga
Design Therapeutics, Getty Images, Sea Limited And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
U.S. stock futures traded lower this morning on Tuesday. Here are some big stocks recording losses in today’s pre-market trading session. 
Via Benzinga
Hanryu Holdings Launches Version 2.0 of Popular K-Culture Fandom Application, FANTOO
Via ACCESSWIRE
Why Is Hanryu Holdings (HRYU) Stock Up 30% Today?
Shareholders in Hanryu and HRYU stock are buying heavily today, as the company announces a key AI-related partnership. 
Via InvestorPlace
Crude Oil Down 1%; Zynerba Pharmaceuticals Shares Spike Higher
U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite gaining around 90 points on Monday. The Dow traded down 0.14% to 35,232.62 while the NASDAQ rose 0.66% to 13,735.42. The... 
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
Why 22nd Century Group Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) shares jumped 283.7% to $1.3007 after Harmony Biosciences entered into definitive agreement to acquire the company for total potential consideration... 
Via Benzinga
US Stocks Turn Higher; BioXcel Therapeutics Shares Plummet
U.S. stocks traded mostly higher midway through trading, with the Nasdaq Composite gaining more than 80 points on Monday. The Dow traded up 0.01% to 35,284.34 while the NASDAQ rose 0.64% to 13,732.05.... 
Via Benzinga
Topics Stocks
Exposures US Equities
Hanryu Holdings (NASDAQ: HRYU) Introduces AI-powered Assistant, Deok Gom, to Boost Engagement on FANTOO Platform
Hanryu Holdings Partners with AI Giant SALTLUX for its FANTOO App Hanryu Holdings, Inc. (NASDAQ: HRYU), known as the backbone 
Via Spotlight Growth
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
Hanryu Holdings Partners with SALTLUX for Development of Artificial Intelligence (AI) Powered Conversational Virtual Assistant on Popular K-Culture Fandom Application, FANTOO
Via ACCESSWIRE
Synthetic THC Researcher Mira Pharmaceuticals Debuts On Nasdaq
Mira Pharmaceuticals made its public debut on the Nasdaq this week. The company raised $8.9 million in its IPO, which it intends to use towards accelerating toxicology and clinical research of its... 
Via Talk Markets
Why Krystal Biotech Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Vistagen Therapeutics, Inc. (NASDAQ: VTGN) shares jumped 747.6% to $14.24 after the company announced its Phase 3 PALISADE-2 trial evaluating the efficacy, safety, and tolerability of... 
Via Benzinga
Aegis Capital Corp. Acted as Sole Bookrunner on a $8.8 Million (IPO) Initial Public Offering for Hanryu Holdings, Inc. (NASDAQ:HRYU)
Via ACCESSWIRE
Hanryu Holdings, Inc. Announces Closing of $8.8 Million Initial Public Offering
Via ACCESSWIRE
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.